Last reviewed · How we verify
NCT04429516: PAciFy Cough
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Phase 3 trial testing Morphine Sulfate in Idiopathic Pulmonary Fibrosis in 44 participants. Completed in 21 March 2023.
21 March 2023
Quick facts
| Lead sponsor | Royal Brompton & Harefield NHS Foundation Trust |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 17 December 2020 |
| Primary completion | 21 March 2023 |
| Estimated completion | 21 March 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Morphine Sulfate — full drug profile →
- Placebo oral tablet — full drug profile →
Conditions studied
- Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Who can join
Adults 40 to 90, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause that results in scarring of the lungs. Cough is reported by 85% of patients with IPF and can be a distressing symptom with significant physical, social and psychological consequences particularly anxiety and depression. The cause of cough in IPF is poorly understood and there are currently no proven effective therapies. Morphine has long been advocated for the suppression of chronic cough in other conditions. While morphine is frequently used as a palliative agent for breathlessness in IPF, its effects on cough have never been tested. The aim of this study is therefore to explore and compare the effect of low dose morphine, one of the few therapies shown to be effective in some patients with otherwise refractory chronic cough, in patients with IPF, to an inactive substance known as a placebo. To make a fair comparison, patients will be randomly allocated to receiving either morphine or placebo in a blinded fashion. This means neither the doctor nor the patient will know which drug they are receiving, and the drugs will appear the same. However, the trial is designed so that you will receive both morphine and placebo, but at different times (this is called a cross-over study). More specifically, you will be given either morphine or placebo for 14 days at a time. In this study, it is hypothesised that compared with placebo, low dose (5mg) controlled release Morphine sulfate (MST) will reduce the number of coughs recorded during a 24hr period in patients with IPF.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.
Wu Z, Spencer LG, Banya W, Westoby J, et al · · 2024 · cited 42× · PMID 38237620 · DOI 10.1016/s2213-2600(23)00432-0 -
Cough in Idiopathic Pulmonary Fibrosis.
Mann J, Goh NSL, Holland AE, Khor YH. · · 2021 · cited 22× · PMID 36188759 · DOI 10.3389/fresc.2021.751798 -
COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives.
Saifi MA, Bansod S, Godugu C. · · 2022 · cited 12× · PMID 36075378 · DOI 10.1016/j.drudis.2022.103345 -
PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.
Wu Z, Banya W, Chaudhuri N, Jakupovic I, et al · · 2022 · cited 12× · PMID 35236391 · DOI 10.1186/s13063-022-06068-4 -
ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly.
Fabbri L, Guiot J, Vermant M, Miądlikowska E, et al · · 2024 · cited 1× · PMID 38529351 · DOI 10.1183/23120541.00839-2023 -
Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases.
Trushenko NV, Suvorova OA, Schmidt AE, Chikina SY, et al · · 2025 · PMID 40361957 · DOI 10.3390/diagnostics15091139 -
PAciFy Cough – A multicentre, double blind, placebo controlled, crossover trial of morphine sulfate for the treatment of PulmonAry Fibrosis Cough
Wu Z, Banya W, Chaudhuri N, Jakupovic I, et al · · 2021 · DOI 10.21203/rs.3.rs-508775/v1
Verify or expand the search:
- PubMed search for NCT04429516
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Morphine Sulfate
Trials testing the same drug.
- NCT07054775 — Comparison of Pruritus Incidence After Intrathecal Morphine 0.1 vs 0.2 mg in Cesarean Section · Phase 4 · recruiting
- NCT05351229 — Intrathecal Morphine for Analgesia in Video-assisted and Robotic-assisted Thoracic Surgery · Phase 4 · recruiting
- NCT05963139 — Comparison of Local Anesthetic Dose in Ipack Block Performed in Knee Arthroplasty Operations · NA · completed
- NCT05324358 — Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy · Phase 3 · completed
- NCT04772222 — Dexmedetomidine Use in Infants Undergoing Cooling Due to Neonatal Encephalopathy (DICE Trial) · Phase 2 · completed
Other recruiting trials for Idiopathic Pulmonary Fibrosis
Currently open trials in the same condition.
- NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
- NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
- NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
- NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
- NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting
Other Royal Brompton & Harefield NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
- NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
- NCT07402434 — A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis · not yet recruiting
- NCT06661278 — Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias · recruiting
- NCT06519240 — A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04429516 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Brompton & Harefield NHS Foundation Trust
- Last refreshed: 14 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04429516.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing